WebApr 10, 2024 · A rating of 81 puts Greenwich Lifesciences Inc ( GLSI) near the top of the Healthcare sector according to InvestorsObserver . Greenwich Lifesciences Inc's score of 81 means that it ranks higher than 81% of stocks in the sector. In addition, its overall score of 57 ranks it higher than 57% of all stocks. GLSI has an Overall Score of 57. WebCancer and Immunotherapy Overview Greenwich LifeSciences, Inc. (GLSI) GP2 Cancer and Immunotherapy A Background on Immunotherapy’s Potential in Defeating Cancer TECHNOLOGY OVERVIEW GP2 PRODUCT IMMUNOTHERAPY BACKGROUND Cancer Immunotherapies are a New Method of Cancer Treatment
Stock Information Greenwich LifeSciences, Inc. (GLSI) GP2
WebApr 13, 2024 · Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) VP Jaye Thompson purchased 1,000 shares of the firm’s stock in a transaction dated Tuesday, … Webabout. management team; board of directors; technology. our gp2 cancer immunotherapy product; cancer and immunotherapy background; clinical trials. completed phase iib clinical trial the range estate croydon
Jaye Thompson Purchases 1,000 Shares of Greenwich LifeSciences, Inc ...
WebJan 5, 2024 · Greenwich LifeSciences, Inc. 13.21 +0.20 +1.58%: TRENDING. 1. Battery maker Northvolt in talks for over $5 billion in financing -FT. 2. Aging Shadow Fleet Carrying Russian Oil Poses Disaster Risk. 3. WebApr 6, 2024 · A high-level overview of Greenwich LifeSciences, Inc. (GLSI) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. WebMar 8, 2024 · Shares of Greenwich LifeSciences ( GLSI 0.80%) were skyrocketing 48.8% higher as of 3:19 p.m. EST on Monday. The huge jump came after the company announced the hiring of Jaye Thompson as vice... signs of a copper deficiency